Abstract Objective To explore the efficacy of neoadjuvant chemoradiotherapy (CRT) followed by surgery for locally advanced esophageal squamous cell carcinoma (ESCC), and to investigate the correlation between a clinical complete response (cCR) and a pathologic complete response (pCR). Methods One hundred and fifty-eight patients with locally advanced thoracic ESCC from 2001 to 2013 were retrospectively analyzed. All patients received concurrent chemoradiotherapy followed by surgery. Platinum-based chemotherapy regimens were adopted in chemotherapy and a prescribed dose of 40 Gy in 20 fractions, 5 fractions per week, was used in radiotherapy. The overall survival (OS) and disease-free survival (DFS) rates were calculated using the Kaplan-Meier method, and pairwise comparisons and univariate prognostic analyses were performed using the log-rank test. Multivariable prognostic analyses were performed using the Cox regression model. Results The pCR rate was 41.1% in all patients. After the treatment with neoadjuvant CRT, 32(72.7%) out of 44 patients with a cCR had a pCR, but only 33(28.9%) out of 114 patients with a non-cCR had a pCR (P=0.000). The sensitivity, specificity, positive predictive value, and negative predictive value of a cCR in predicting a pCR were 49.2%, 87.1%, 72.7%, and 71.1%, respectively. The 3-year sample size was 91. The 3-year OS and DFS rates in all patients were 53.9% and 48.6%, respectively. Patients with a cCR had significantly higher 3-year OS and DFS rates than those with a non-cCR (P=0.012;P=0.026), while patients with a pCR had significantly higher 3-year OS and DFS rates than those with a non-pCR (P=0.000;P=0.000). The multivariate analyses demonstrated that the pathologic response after CRT and chemotherapy regimen were the influencing factors for OS. The most common grade ≥3 acute adverse reaction was leucopenia (34.2%). Conclusions With a high pCR rate and tolerable adverse reactions, neoadjuvant CRT followed by surgery is a safe and effective option for locally advanced ESCC. The cCR rate after CRT is closely correlated with the pCR and OS rates.
Corresponding Authors:
Liu Mengzhong,Email:liumengzhong@126.com
Cite this article:
Liu Shiliang*,Xi Mian,Yang Yadi et al. Clinical efficacy of neoadjuvant chemoradiotherapy followed by surgery for locally advanced esophageal squamous cell carcinoma[J]. Chinese Journal of Radiation Oncology, 2015, 24(3): 232-236.
Liu Shiliang*,Xi Mian,Yang Yadi et al. Clinical efficacy of neoadjuvant chemoradiotherapy followed by surgery for locally advanced esophageal squamous cell carcinoma[J]. Chinese Journal of Radiation Oncology, 2015, 24(3): 232-236.
[1] van Hagen P,Hulshof MC,van Lanschot JJ,et al. Preoperative chemoradiotherapy for esophageal or junctional cancer[J]. N Engl J Med,2012,366(22):2074-2084.DOI:10.1056/NEJMoa1112088. [2] Sjoquist KM,Burmeister BH,Smithers BM,et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma:an updated Meta-analysis[J]. Lancet Oncol,2011,12(7):681-692.DOI:10.1016/S1470-2045(11)70142-5. [3] Ronellenfitsch U,Schwarzbach M,Hofheinz R,et al. Preoperative chemo (radio) therapy versus primary surgery for gastroesophageal adenocarcinoma:systematic review with Meta-analysis combining individual patient and aggregate data[J]. Eur J Cancer,2013,49(15):3149-3158.DOI:10.1016/j.ejca.2013.05.029. [4] Tepper J,Krasna MJ,Niedzwiecki D,et al. Phase Ⅲ trial of trimodality therapy with cisplatin,fluorouracil,radiotherapy,and surgery compared with surgery alone for esophageal cancer:CALGB 9781[J].J Clin Oncol,2008,26(7):1086-1092.DOI:10.1200/JCO.2007.12.9593. [5] Scheer RV,Fakiris AJ,Johnstone PA. Quantifying the benefit of a pathologic complete response after neoadjuvant chemoradiotherapy in the treatment of esophageal cancer[J]. Int J Radiat Oncol Biol Phys,2011,80(4):996-1001.DOI:10.1016/j.ijrobp.2010.03.003. [6] Bollschweiler E,Holscher AH,Metzger R. Histologic tumor type and the rate of complete response after neoadjuvant therapy for esophageal cancer[J]. Future Oncol,2010,6(1):25-35.DOI:10.2217/fon.09.133. [7] Gebski V,Burmeister B,Smithers BM,et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma:a Meta-analysis[J]. Lancet Oncol,2007,8(3):226-234. [8] Siewert JR,Ott K. Are squamous and adenocarcinomas of the esophagus the same disease?[J]. Semin Radiat Oncol,2007,17(1):38-44. [9] Cheedella NK,Suzuki A,Xiao L,et al. Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer:analysis in a large cohort[J]. Ann Oncol,2013,24(5):1262-1266.DOI:10.1093/annonc/mds617. [10] Akutsu Y,Matsubara H,Shuto K,et al. Clinical and pathologic evaluation of the effectiveness of neoadjuvant chemoradiation therapy in advanced esophageal cancer patients[J]. World J Surg,2009,33(5):1002-1009.DOI:10.1007/s00268-008-9899-8. [11] Castoro C,Scarpa M,Cagol M,et al. Complete clinical response after neoadjuvant chemoradiotherapy for squamous cell cancer of the thoracic oesophagus:is surgery always necessary?[J]. J Gastrointest Surg,2013,17(8):1375-1381. [12] Piessen G,Messager M,Mirabel X,et al. Is there a role for surgery for patients with a complete clinical response after chemoradiation for esophageal cancer? An intention-to-treat case-control study[J]. Ann Surg,2013,258(5):793-799.DOI:10.1097/SLA.0000000000000228. [13] Zhang SS,Huang QY,Yang H,et al. Correlation of p53 status with the response to chemotherapy-based treatment in esophageal cancer:a Meta-analysis[J]. Ann Surg Oncol,2013,20(7):2419-2427.DOI:10.1245/s10434-012-2859-4. [14] Wen J,Yang H,Liu MZ,et al. Gene expression analysis of pretreatment biopsies predicts the pathological response of esophageal squamous cell carcinoma stoneo-chemoradiotherapy[J].Ann Oncol,2014,25(9):1769-1774.DOI:10.1093/annonc/mdu201. [15] Richel DJ,Vervenne WL. Systemic treatment of oesophageal cancer[J]. Eur J Gastroenterol Hepatol,2004,16(3):249-254. [16] Boggs DH,Tarabolous C,Morris CG,et al. Analysis of pathological complete response rates with paclitaxel-based regimens in trimodality therapy for esophageal cancer [J/OL].Dis Esophagus,2014[2014-10-10].http://onlinelibrary.wiley.com/doi/10.1111/dote.12243/abstract;jsessionid=BEC6AD153BF37C860E155BE1AB67BE/B.f04t02.DOI:10.1111/dote.12243.
2015, Vol. 24 
